Basel, Switzerland – 26 September 2016: Nouscom, an oncology company developing patient specific cancer vaccines based on a clinically validated genetic vaccine platform, today announced the appointment of Dr Marina [...]
Myasthenia gravis and immune thrombocytopenia named as initial indications for Phase 2 studies of ARGX-113
T-cell lymphoma and acute myeloid leukemia named as indications for Phase 2 combination studies for [...]
Advancements to Stent Retriever Platform Designed to Enhance Procedure
Galway, Ireland – September 8, 2016 - Neuravi, a company dedicated to improving clinical outcomes for stroke patients, today announced [...]
Amsterdam, the Netherlands —September 8, 2016 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series C Round of Vivasure Medical, a private Irish company [...]
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model
In an acute peritonitis model PQ912 inhibits monocyte infiltration, increases eosinophils and enhan [...]
Launch follows successful completion of CE Performance Evaluation Study
ITI now covers 102 diagnostic targets, including 85 pathogens and 17 resistance markers
Amsterdam, the Netherlands, and Hol [...]
6th September 2016
ViCentra, manufacturer of the Kaleido insulin delivery system, today announced the appointment of Dr. David Kerr and Dr. Fred Storms as medical and scientific advisors to its team. Drs. K [...]
Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
Phase 2 study in first auto-immune indication planned to start by year-end
Cash position strengthened by $40M up [...]
Amsterdam, the Netherlands, August 25, 2016 – LSP’s portfolio company Mint Solutions Holding BV, a private Dutch company developing and marketing the revolutionary medication safety system MedEye, has raised €5 [...]
Basel, Switzerland – 26 September 2016: Nouscom, an oncology company developing patient specific cancer vaccines based on a clinically validated genetic vaccine platform, today announced the appointment of Dr Marina [...]
Myasthenia gravis and immune thrombocytopenia named as initial indications for Phase 2 studies of ARGX-113
T-cell lymphoma and acute myeloid leukemia named as indications for Phase 2 combination studies for [...]
Advancements to Stent Retriever Platform Designed to Enhance Procedure
Galway, Ireland – September 8, 2016 - Neuravi, a company dedicated to improving clinical outcomes for stroke patients, today announced [...]
Amsterdam, the Netherlands —September 8, 2016 — LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series C Round of Vivasure Medical, a private Irish company [...]
Promising new findings for Probiodrug's Glutaminyl Cyclase - inhibitor in an inflammation animal model
In an acute peritonitis model PQ912 inhibits monocyte infiltration, increases eosinophils and enhan [...]
Launch follows successful completion of CE Performance Evaluation Study
ITI now covers 102 diagnostic targets, including 85 pathogens and 17 resistance markers
Amsterdam, the Netherlands, and Hol [...]
6th September 2016
ViCentra, manufacturer of the Kaleido insulin delivery system, today announced the appointment of Dr. David Kerr and Dr. Fred Storms as medical and scientific advisors to its team. Drs. K [...]
Successful Phase 1 multiple ascending dose (MAD) study of ARGX-113 in healthy volunteers
Phase 2 study in first auto-immune indication planned to start by year-end
Cash position strengthened by $40M up [...]
Amsterdam, the Netherlands, August 25, 2016 – LSP’s portfolio company Mint Solutions Holding BV, a private Dutch company developing and marketing the revolutionary medication safety system MedEye, has raised €5 [...]
Follow us
